{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T18:31:57Z","timestamp":1792348317664,"version":"4.4.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Graves' disease (GD) is an autoimmune disorder characterized by activation of the TSH receptor by stimulatory autoantibodies (TSH Receptor Antibodies, or TRAbs), leading to unregulated thyroid hormone production. Diagnosis is largely based on the typical clinical picture and laboratory thyroid panel. Establishment of elevated serum levels of TRAbs by competitive binding assay or cell-binding assay has its unique role in diagnosis and management of GD, especially in the differential diagnosis, therapy selection, prognostication, evaluation of thyroid function during pregnancy, peri-conceptional and neonatal thyroid workup, and in certain special situation. Inclusion of TRAbs in GD diagnostic algorithm can improve cost-effectiveness of GD management. The current best practice guidelines were developed to provide evidence-based recommendations in the use of TRABs in GD management for healthcare providers in South Asia. A panel of endocrinologists with minimum 10\u00a0years of clinical experience in thyroid disorders reviewed existing literature and their quality, and after deliberation and discussion, developed 21 recommendations surrounding the best practices surrounding the role of TRAbs in GD management.<\/jats:p>","DOI":"10.1186\/s12902-024-01809-9","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T03:24:51Z","timestamp":1734751491000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Best practices in the laboratory diagnosis, prognostication, prediction, and monitoring of Graves\u2019 disease: role of TRAbs"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1308-121X","authenticated-orcid":false,"given":"Sanjay","family":"Kalra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahjada","family":"Selim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Somasundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Abbas","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manash P.","family":"Baruah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saptarshi","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharvil","family":"Gadve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganapathi","family":"Bantwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Sahay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,21]]},"reference":[{"key":"1809_CR1","doi-asserted-by":"publisher","first-page":"101010","DOI":"10.1016\/j.cegh.2022.101010","volume":"15","author":"J Sengupta","year":"2022","unstructured":"Sengupta J, Das H, Sasithra S, Britto J. An observational study of incidence of metabolic syndrome among patients with controlled Grave\u2019s disease. Clin Epidemiol Glob Health. 2022;15:101010.","journal-title":"Clin Epidemiol Glob Health"},{"key":"1809_CR2","unstructured":"Pokhrel B, Bhusal K: Graves Disease. In: StatPearls. edn. Treasure Island (FL): StatPearls Publishing; 2022."},{"issue":"Suppl","key":"1809_CR3","first-page":"26","volume":"59","author":"RK Sahay","year":"2011","unstructured":"Sahay RK. Thyrotoxicosis. J Assoc Physicians India. 2011;59(Suppl):26\u201331.","journal-title":"J Assoc Physicians India"},{"issue":"10","key":"1809_CR4","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343\u2013421.","journal-title":"Thyroid"},{"issue":"4","key":"1809_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000490384","volume":"7","author":"GJ Kahaly","year":"2018","unstructured":"Kahaly GJ, Bartalena L, Heged\u00fcs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves\u2019 Hyperthyroidism. Eur Thyroid J. 2018;7(4):167\u201386.","journal-title":"Eur Thyroid J"},{"issue":"3","key":"1809_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1089\/thy.2016.0457","volume":"27","author":"EK Alexander","year":"2017","unstructured":"Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, Grobman WA, Laurberg P, Lazarus JH, Mandel SJ, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27(3):315\u201389.","journal-title":"Thyroid"},{"key":"1809_CR7","doi-asserted-by":"crossref","unstructured":"Mooij CF, Cheetham TD, Verburg FA, Eckstein A, Pearce SH, L\u00e9ger J, van Trotsenburg ASP: 2022 European Thyroid Association Guideline for the management of pediatric Graves' disease. Eur Thyroid J 2022, 11(1).","DOI":"10.1530\/ETJ-21-0073"},{"issue":"2","key":"1809_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1297\/cpe.26.29","volume":"26","author":"K Minamitani","year":"2017","unstructured":"Minamitani K, Sato H, Ohye H, Harada S, Arisaka O. Guidelines for the treatment of childhood-onset Graves\u2019 disease in Japan, 2016. Clin Pediatr Endocrinol. 2017;26(2):29\u201362.","journal-title":"Clin Pediatr Endocrinol"},{"issue":"1","key":"1809_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4103\/2230-8210.77566","volume":"15","author":"AG Unnikrishnan","year":"2011","unstructured":"Unnikrishnan AG, Kalra S, Baruah M, Nair G, Nair V, Bantwal G, Sahay RK. Endocrine Society of India management guidelines for patients with thyroid nodules: A position statement. Indian J Endocrinol Metab. 2011;15(1):2\u20138.","journal-title":"Indian J Endocrinol Metab"},{"issue":"1","key":"1809_CR10","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12916-022-02544-5","volume":"20","author":"A Sharma-Oates","year":"2022","unstructured":"Sharma-Oates A, Zemedikun DT, Kumar K, Reynolds JA, Jain A, Raza K, Williams JA, Bravo L, Cardoso VR, Gkoutos G, et al. Early onset of immune-mediated diseases in minority ethnic groups in the UK. BMC Med. 2022;20(1):346.","journal-title":"BMC Med"},{"key":"1809_CR11","doi-asserted-by":"crossref","unstructured":"Subramanian A, Adderley NJ, Gkoutos GV, Gokhale KM, Nirantharakumar K, Krishna MT: Ethnicity-based differences in the incident risk of allergic diseases and autoimmune disorders: A UK-based retrospective cohort study of 4.4 million participants. Clin Exp Allergy 2021, 51(1):144\u2013147.","DOI":"10.1111\/cea.13741"},{"key":"1809_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3389\/fendo.2017.00028","volume":"8","author":"GJ Kahaly","year":"2017","unstructured":"Kahaly GJ, Diana T. TSH Receptor Antibody Functionality and Nomenclature. Front Endocrinol (Lausanne). 2017;8:28.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1809_CR13","doi-asserted-by":"crossref","unstructured":"Kotwal A, Stan M: Thyrotropin Receptor Antibodies-An Overview. Ophthalmic Plast Reconstr Surg 2018, 34(4S Suppl 1):S20-s27.","DOI":"10.1097\/IOP.0000000000001052"},{"key":"1809_CR14","unstructured":"Adams DD: Abnormal responses in the assay of thyrotropin. In: Proc Univ Otago Med School: 1956; 1956: 11\u201312."},{"issue":"2","key":"1809_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.autrev.2009.03.012","volume":"9","author":"K Michalek","year":"2009","unstructured":"Michalek K, Morshed SA, Latif R, Davies TF. TSH receptor autoantibodies. Autoimmun Rev. 2009;9(2):113\u20136.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"1809_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4158\/EP-2019-0363","volume":"26","author":"GJ Kahaly","year":"2020","unstructured":"Kahaly GJ, Diana T, Olivo PD. TSH receptor antibodies: relevance & utility. Endocr Pract. 2020;26(1):97\u2013106.","journal-title":"Endocr Pract"},{"key":"1809_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jaut.2013.07.009","volume":"47","author":"SA Morshed","year":"2013","unstructured":"Morshed SA, Ma R, Latif R, Davies TF. How one TSH receptor antibody induces thyrocyte proliferation while another induces apoptosis. J Autoimmun. 2013;47:17\u201324.","journal-title":"J Autoimmun"},{"issue":"5","key":"1809_CR18","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/cen.13327","volume":"86","author":"A HesarghattaShyamasunder","year":"2017","unstructured":"HesarghattaShyamasunder A, Abraham P. Measuring TSH receptor antibody to influence treatment choices in Graves\u2019 disease. Clin Endocrinol (Oxf). 2017;86(5):652\u20137.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"1809_CR19","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1089\/1050725042451248","volume":"14","author":"BR Smith","year":"2004","unstructured":"Smith BR, Bolton J, Young S, Collyer A, Weeden A, Bradbury J, Weightman D, Perros P, Sanders J, Furmaniak J. A new assay for thyrotropin receptor autoantibodies. Thyroid. 2004;14(10):830\u20135.","journal-title":"Thyroid"},{"issue":"4","key":"1809_CR20","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/j.1365-2265.2008.03512.x","volume":"71","author":"M Schott","year":"2009","unstructured":"Schott M, Hermsen D, Broecker-Preuss M, Casati M, Mas JC, Eckstein A, Gassner D, Golla R, Graeber C, van Helden J, et al. Clinical value of the first automated TSH receptor autoantibody assay for the diagnosis of Graves\u2019 disease (GD): an international multicentre trial. Clin Endocrinol (Oxf). 2009;71(4):566\u201373.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"1809_CR21","doi-asserted-by":"publisher","first-page":"e0270890","DOI":"10.1371\/journal.pone.0270890","volume":"17","author":"JM L\u00f3pez Ortega","year":"2022","unstructured":"L\u00f3pez Ortega JM, Mart\u00ednez PS, Acevedo-Le\u00f3n D, Capell NE. Anti-TSH receptor antibodies (TRAb): Comparison of two third generation automated immunoassays broadly used in clinical laboratories and results interpretation. PLoS ONE. 2022;17(7):e0270890.","journal-title":"PLoS ONE"},{"issue":"2","key":"1809_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s13317-010-0014-4","volume":"1","author":"R Tozzoli","year":"2010","unstructured":"Tozzoli R, Kodermaz G, Villalta D, Bagnasco M, Pesce G, Bizzaro N. Accuracy of receptor-based methods for detection of thyrotropin-receptor autoantibodies: a new automated third-generation immunoassay shows higher analytical and clinical sensitivity for the differential diagnosis of hyperthyroidism. Auto Immun Highlights. 2010;1(2):95\u2013100.","journal-title":"Auto Immun Highlights"},{"key":"1809_CR23","doi-asserted-by":"publisher","first-page":"525936","DOI":"10.1155\/2012\/525936","volume":"2012","author":"C Kamath","year":"2012","unstructured":"Kamath C, Adlan MA, Premawardhana LD. The role of thyrotrophin receptor antibody assays in graves\u2019 disease. J Thyroid Res. 2012;2012:525936\u2013525936.","journal-title":"J Thyroid Res"},{"issue":"1","key":"1809_CR24","first-page":"e1","volume":"18","author":"A McKee","year":"2012","unstructured":"McKee A, Peyerl F. TSI assay utilization: impact on costs of Graves\u2019 hyperthyroidism diagnosis. Am J Manag Care. 2012;18(1):e1-14.","journal-title":"Am J Manag Care"},{"issue":"6","key":"1809_CR25","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1210\/jc.2012-4309","volume":"98","author":"G Barbesino","year":"2013","unstructured":"Barbesino G, Tomer Y. Clinical review: Clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab. 2013;98(6):2247\u201355.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7650","key":"1809_CR26","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924.","journal-title":"BMJ"},{"issue":"3","key":"1809_CR27","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1001\/archinte.1989.00390030032006","volume":"149","author":"delos Santos ET,","year":"1989","unstructured":"delos Santos ET,. Starich GH, Mazzaferri EL: Sensitivity, specificity, and cost-effectiveness of the sensitive thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients. Arch Intern Med. 1989;149(3):526\u201332.","journal-title":"Arch Intern Med"},{"issue":"2","key":"1809_CR28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.autrev.2012.07.003","volume":"12","author":"R Tozzoli","year":"2012","unstructured":"Tozzoli R, Bagnasco M, Giavarina D, Bizzaro N. TSH receptor autoantibody immunoassay in patients with Graves\u2019 disease: improvement of diagnostic accuracy over different generations of methods Systematic review and meta-analysis. Autoimmun Rev. 2012;12(2):107\u201313.","journal-title":"Autoimmun Rev"},{"key":"1809_CR29","doi-asserted-by":"publisher","first-page":"5945178","DOI":"10.1155\/2019\/5945178","volume":"2019","author":"J Karmisholt","year":"2019","unstructured":"Karmisholt J, Andersen SL, Bulow-Pedersen I, Carl\u00e9 A, Krejbjerg A, Nygaard B. Predictors of initial and sustained remission in patients treated with antithyroid drugs for Graves\u2019 hyperthyroidism: the RISG study. J Thyroid Res. 2019;2019:5945178.","journal-title":"J Thyroid Res"},{"issue":"5","key":"1809_CR30","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1507\/endocrj.K06-069","volume":"54","author":"C Cappelli","year":"2007","unstructured":"Cappelli C, Gandossi E, Castellano M, Pizzocaro C, Agosti B, Delbarba A, Pirola I, De Martino E, Rosei EA. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves\u2019 disease: a 120 months prospective study. Endocr J. 2007;54(5):713\u201320.","journal-title":"Endocr J"},{"issue":"5","key":"1809_CR31","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1210\/jc.2018-01738","volume":"104","author":"A Bano","year":"2019","unstructured":"Bano A, Gan E, Addison C, Narayanan K, Weaver JU, Tsatlidis V, Razvi S. Age may influence the impact of TRAbs on thyroid function and relapse-risk in patients with Graves disease. J Clin Endocrinol Metab. 2019;104(5):1378\u201385.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1809_CR32","first-page":"248","volume":"58","author":"A Bojarska-Szmygin","year":"2003","unstructured":"Bojarska-Szmygin A, Janicki K, Pietura R, Janicka L. Changes in TSH receptor antibody levels (TRAb) as markers of effectiveness of various therapies in Graves-Basedow\u2019s disease. Ann Univ Mariae Curie Sklodowska Med. 2003;58(1):248\u201353.","journal-title":"Ann Univ Mariae Curie Sklodowska Med"},{"issue":"4","key":"1809_CR33","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1210\/jc.2015-3644","volume":"101","author":"XG Vos","year":"2016","unstructured":"Vos XG, Endert E, Zwinderman AH, Tijssen JG, Wiersinga WM. Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves\u2019 hyperthyroidism. J Clin Endocrinol Metab. 2016;101(4):1381\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1809_CR34","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1530\/EJE-16-0986","volume":"176","author":"T Struja","year":"2017","unstructured":"Struja T, Kaeslin M, Boesiger F, Jutzi R, Imahorn N, Kutz A, Bernasconi L, Mundwiler E, Mueller B, Christ-Crain M, et al. External validation of the GREAT score to predict relapse risk in Graves\u2019 disease: results from a multicenter, retrospective study with 741 patients. Eur J Endocrinol. 2017;176(4):413\u20139.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1809_CR35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1590\/S0004-27302013000300005","volume":"57","author":"GA Carvalho","year":"2013","unstructured":"Carvalho GA, Perez CL, Ward LS. The clinical use of thyroid function tests. Arq Bras Endocrinol Metabol. 2013;57(3):193\u2013204.","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"1","key":"1809_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3803\/EnM.2019.34.1.29","volume":"34","author":"WM Wiersinga","year":"2019","unstructured":"Wiersinga WM. Graves\u2019 Disease: Can It Be Cured? Endocrinol Metab (Seoul). 2019;34(1):29\u201338.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"Suppl 1","key":"1809_CR37","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.4103\/2230-8210.119513","volume":"17","author":"R Rajput","year":"2013","unstructured":"Rajput R, Goel V. Indefinite antithyroid drug therapy in toxic Graves\u2019 disease: What are the cons. Indian J Endocrinol Metab. 2013;17(Suppl 1):S88-92.","journal-title":"Indian J Endocrinol Metab"},{"key":"1809_CR38","doi-asserted-by":"crossref","unstructured":"Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS: Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst Rev 2010, 2010(1):Cd003420.","DOI":"10.1002\/14651858.CD003420.pub4"},{"issue":"Suppl1","key":"1809_CR39","first-page":"1","volume":"18","author":"H Abdi","year":"2019","unstructured":"Abdi H, Amouzegar A, Azizi F. Antithyroid Drugs. Iran J Pharm Res. 2019;18(Suppl1):1\u201312.","journal-title":"Iran J Pharm Res"},{"issue":"3","key":"1809_CR40","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S2213-8587(13)70086-X","volume":"1","author":"DS Cooper","year":"2013","unstructured":"Cooper DS, Laurberg P. Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol. 2013;1(3):238\u201349.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1809_CR41","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/cen.13731","volume":"89","author":"OE Okosieme","year":"2018","unstructured":"Okosieme OE, Khan I, Taylor PN. Preconception management of thyroid dysfunction. Clin Endocrinol (Oxf). 2018;89(3):269\u201379.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1809_CR42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40842-018-0054-7","volume":"4","author":"CT Nguyen","year":"2018","unstructured":"Nguyen CT, Sasso EB, Barton L, Mestman JH. Graves\u2019 hyperthyroidism in pregnancy: a clinical review. Clin Diabetes Endocrinol. 2018;4:4.","journal-title":"Clin Diabetes Endocrinol"},{"issue":"5","key":"1809_CR43","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/MED.0000000000000088","volume":"21","author":"P Laurberg","year":"2014","unstructured":"Laurberg P, Krejbjerg A, Andersen SL. Relapse following antithyroid drug therapy for Graves\u2019 hyperthyroidism. Curr Opin Endocrinol Diabetes Obes. 2014;21(5):415\u201321.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"6","key":"1809_CR44","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1055\/s-0036-1593489","volume":"34","author":"S Sarkar","year":"2016","unstructured":"Sarkar S, Bischoff LA. Management of hyperthyroidism during the preconception phase, pregnancy, and the postpartum period. Semin Reprod Med. 2016;34(6):317\u201322.","journal-title":"Semin Reprod Med"},{"issue":"1","key":"1809_CR45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1530\/EJE-07-0450","volume":"158","author":"P Laurberg","year":"2008","unstructured":"Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, T\u00f8rring O. TSH-receptor autoimmunity in Graves\u2019 disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol. 2008;158(1):69\u201375.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1809_CR46","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000339473","volume":"1","author":"S Kautbally","year":"2012","unstructured":"Kautbally S, Alexopoulou O, Daumerie C, Jamar F, Mourad M, Maiter D. Greater efficacy of total thyroidectomy versus radioiodine therapy on hyperthyroidism and thyroid-stimulating immunoglobulin levels in patients with Graves\u2019 disease previously treated with antithyroid drugs. Eur Thyroid J. 2012;1(2):122\u20138.","journal-title":"Eur Thyroid J"},{"issue":"6","key":"1809_CR47","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1210\/jcem.86.6.7573","volume":"86","author":"SJ Mandel","year":"2001","unstructured":"Mandel SJ, Cooper DS. The use of antithyroid drugs in pregnancy and lactation. J Clin Endocrinol Metab. 2001;86(6):2354\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1809_CR48","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1210\/jc.2014-3588","volume":"100","author":"SL Andersen","year":"2015","unstructured":"Andersen SL, Olsen J, Carl\u00e9 A, Laurberg P. Hyperthyroidism incidence fluctuates widely in and around pregnancy and is at variance with some other autoimmune diseases: a Danish population-based study. J Clin Endocrinol Metab. 2015;100(3):1164\u201371.","journal-title":"J Clin Endocrinol Metab"},{"key":"1809_CR49","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.clinbiochem.2018.11.017","volume":"64","author":"Y Li","year":"2019","unstructured":"Li Y, Xu T, Mo Q, Fu W, Yao C. Thyrotropin receptor antibody: A novel risk indicator for pregnancy loss. Clin Biochem. 2019;64:44\u20138.","journal-title":"Clin Biochem"},{"issue":"1","key":"1809_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000453065","volume":"87","author":"J L\u00e9ger","year":"2017","unstructured":"L\u00e9ger J. Management of fetal and neonatal Graves\u2019 disease. Horm Res Paediatr. 2017;87(1):1\u20136.","journal-title":"Horm Res Paediatr"},{"issue":"6","key":"1809_CR51","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1530\/EJE-13-0994","volume":"170","author":"A Besan\u00e7on","year":"2014","unstructured":"Besan\u00e7on A, Beltrand J, Le Gac I, Luton D, Polak M. Management of neonates born to women with Graves\u2019 disease: a cohort study. Eur J Endocrinol. 2014;170(6):855\u201362.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1809_CR52","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1530\/EJE-14-0254","volume":"171","author":"J Abeillon-du Payrat","year":"2014","unstructured":"Abeillon-du Payrat J, Chikh K, Bossard N, Bretones P, Gaucherand P, Claris O, Charri\u00e9 A, Raverot V, Orgiazzi J, Borson-Chazot F, et al. Predictive value of maternal second-generation thyroid-binding inhibitory immunoglobulin assay for neonatal autoimmune hyperthyroidism. Eur J Endocrinol. 2014;171(4):451\u201360.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1809_CR53","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1210\/js.2017-00189","volume":"1","author":"M Banig\u00e9","year":"2017","unstructured":"Banig\u00e9 M, Estellat C, Biran V, Desfrere L, Champion V, Benachi A, Ville Y, Dommergues M, Jarreau PH, Mokhtari M, et al. Study of the factors leading to fetal and neonatal dysthyroidism in children of patients with Graves disease. J Endocr Soc. 2017;1(6):751\u201361.","journal-title":"J Endocr Soc"},{"key":"1809_CR54","unstructured":"Naji Rad S, Deluxe L: Postpartum Thyroiditis. In: StatPearls. edn. Treasure Island (FL): StatPearls Publishing; 2022."},{"key":"1809_CR55","doi-asserted-by":"publisher","first-page":"8871951","DOI":"10.1155\/2020\/8871951","volume":"2020","author":"C Li","year":"2020","unstructured":"Li C, Zhou J, Huang Z, Pan X, Leung W, Chen L, Zhang Y, Wang L, Sima Y, Gober HJ, et al. The clinical value and variation of antithyroid antibodies during pregnancy. Dis Markers. 2020;2020:8871951.","journal-title":"Dis Markers"},{"issue":"1","key":"1809_CR56","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1687-9856-2014-10","volume":"2014","author":"SA Rivkees","year":"2014","unstructured":"Rivkees SA. Pediatric Graves\u2019 disease: management in the post-propylthiouracil Era. Int J Pediatr Endocrinol. 2014;2014(1):10.","journal-title":"Int J Pediatr Endocrinol"},{"issue":"11","key":"1809_CR57","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1089\/thy.2007.0072","volume":"17","author":"J Smith","year":"2007","unstructured":"Smith J, Brown RS. Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves\u2019 disease treated using antithyroid medication. Thyroid. 2007;17(11):1103\u20137.","journal-title":"Thyroid"},{"issue":"5","key":"1809_CR58","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.jpeds.2013.12.047","volume":"164","author":"R Gastaldi","year":"2014","unstructured":"Gastaldi R, Poggi E, Mussa A, Weber G, Vigone MC, Salerno M, Delvecchio M, Peroni E, Pistorio A, Corrias A. Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers. J Pediatr. 2014;164(5):1189-1194.e1181.","journal-title":"J Pediatr"},{"issue":"5","key":"1809_CR59","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1210\/jc.2013-4026","volume":"99","author":"T Diana","year":"2014","unstructured":"Diana T, Brown RS, Bossowski A, Segni M, Niedziela M, K\u00f6nig J, Bossowska A, Ziora K, Hale A, Smith J, et al. Clinical relevance of thyroid-stimulating autoantibodies in pediatric graves\u2019 disease-a multicenter study. J Clin Endocrinol Metab. 2014;99(5):1648\u201355.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1809_CR60","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/eye.2013.120","volume":"27","author":"SY Jang","year":"2013","unstructured":"Jang SY, Shin DY, Lee EJ, Lee SY, Yoon JS. Relevance of TSH-receptor antibody levels in predicting disease course in Graves\u2019 orbitopathy: comparison of the third-generation TBII assay and Mc4-TSI bioassay. Eye (Lond). 2013;27(8):964\u201371.","journal-title":"Eye (Lond)"},{"issue":"9","key":"1809_CR61","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1210\/jc.2005-2813","volume":"91","author":"AK Eckstein","year":"2006","unstructured":"Eckstein AK, Plicht M, Lax H, Neuh\u00e4user M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG. Thyrotropin receptor autoantibodies are independent risk factors for Graves\u2019 ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006;91(9):3464\u201370.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1809_CR62","first-page":"542","volume":"79","author":"AW Kung","year":"1994","unstructured":"Kung AW, Yau CC, Cheng A. The incidence of ophthalmopathy after radioiodine therapy for Graves\u2019 disease: prognostic factors and the role of methimazole. J Clin Endocrinol Metab. 1994;79(2):542\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1809_CR63","doi-asserted-by":"publisher","first-page":"711","DOI":"10.14740\/jocmr4352","volume":"12","author":"C Lan","year":"2020","unstructured":"Lan C, Hu L, Liao C, Shi Y, Wang Y, Cheng S, Huang W. Thyroid-stimulating hormone receptor autoimmunity and local factors in multiple risk factors are mainly involved in the occurrence of pretibial myxedema. J Clin Med Res. 2020;12(11):711\u201323.","journal-title":"J Clin Med Res"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-024-01809-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-024-01809-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-024-01809-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T05:12:26Z","timestamp":1734757946000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-024-01809-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1809"],"URL":"https:\/\/doi.org\/10.1186\/s12902-024-01809-9","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,21]]},"assertion":[{"value":"5 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since this is an expert opinion about the best practices in the laboratory diagnosis, management, prognosis, and monitoring of Graves\u2019 Disease, and no human clinical data was collected, ethics committee approval was not deemed to be necessary by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"274"}}